z-logo
Premium
Tetracycline treatment in patients with progressive external ophthalmoplegia
Author(s) -
Mancuso M.,
Orsucci D.,
Calsolaro V.,
LoGerfo A.,
Allegrini L.,
Petrozzi L.,
Simoncini C.,
Rocchi A.,
Trivella F.,
Murri L.,
Siciliano G.
Publication year - 2011
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2011.01536.x
Subject(s) - tetracycline , external ophthalmoplegia , medicine , chronic progressive external ophthalmoplegia , chemistry , antibiotics , mitochondrial myopathy , mitochondrial dna , gene , biochemistry
Mancuso M, Orsucci D, Calsolaro V, LoGerfo A, Allegrini L, Petrozzi L, Simoncini C, Rocchi A, Trivella F, Murri L, Siciliano G.
Tetracycline treatment in patients with progressive external ophthalmoplegia.
Acta Neurol Scand: 2011: 124: 417–423.
© 2011 John Wiley & Sons A/S. Background –  Tetracyclines could have neuroprotective effects in neuromuscular and neurodegenerative disorders. Aims of the study and methods –  Objective of this double‐blind randomized pilot study (followed by an adjunctive open‐label phase) was to evaluate whether tetracycline (500 mg/day × 14 days/month × 3 months) could be useful in patients (n = 16) with progressive external ophthalmoplegia (PEO). Results –  Our results do not formally support any effect of tetracycline on eye motility in PEO. However, some possible protective effects could not be completely ruled out, i.e. a further analysis suggests a possible difference between the tetracycline group and the placebo group, significant at least for oblique motility, when comparing the ratio between the end of the double‐blind phase and baseline. Tetracycline could modify some oxidative stress biomarkers in patients with PEO. Conclusions –  Further studies are needed to confirm such effects of tetracycline in patients with PEO, if any, and to clarify the mechanisms of action for antioxidant effects of tetracyclines in mitochondrial disorders and other diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here